Clinical trials: Seizure Disorders
- Condition Seizure Disorders
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Epilepsy, Epilepsy, Temporal Lobe
Brain Network Activation Analysis in Epilepsy
This is a prospective study investigating the utility of Brain Network Activation (BNA) analysis in patients with epilepsy.
- Trial name
- NCT03265925
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Hearing Loss
Comparison of Hearing Aid Fitting Outcomes Between Self-fit and Professional Fit for MDHearing Smart Hearing Aids
Hearing aids are commonly used to help people with hearing loss hear better in daily listening environments. MDHearing Smart hearing aids are designed to use the MDHearing app to adjust hearing aids to each individual's hearing…
- Trial name
- NCT05165121
- Testing
- MDHearing smart hearing aid
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- MDHearingAid
Epilepsy
Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Phase I, two-centre, open-label, randomized, gender-balanced, single-dose, laboratory blinded, two-period, two-sequence, crossover study in 2 groups of 20 healthy male and female subjects, to demonstrate the bioequivalence (BE)…
- Trial name
- NCT02284880
- Testing
- BIA 2-093
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects
Primary objective of this trial was to investigate the pharmacokinetics of single dose and repeated dose applications of lacosamide in healthy male Korean subjects.
- Trial name
- NCT01450111
- Testing
- Lacosamide
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Epilepsy
Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9 males and 9 females). The study consisted of three consecutive single-dose treatment periods separated by a washout period of 7 days or…
- Trial name
- NCT02279667
- Testing
- BIA 2-093
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Seizures
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, folloiwng a single 600 mg dose…
- Trial name
- NCT00616863
- Testing
- Oxcarbazepine
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Hearing Loss
Evaluation of New Fitting Characteristics for Extended Wear Hearing Aid Technology
Two groups of hearing aid candidates will be fit with extended wear technology. One group will be fit with the commercially available models, and the other group will be fit with either the commercially available model or a new…
- Trial name
- NCT05274165
- Testing
- Lyric Hearing Aid- Experimental Design, Lyric Hearing Aid- Commercially Available
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sonova AG
Seizures
Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures
This is a Phase IV adjunctive treatment dose-optimization study evaluating the efficacy, safety, and health outcomes of ezogabine/retigabine immediate release (IR) (GW582892) compared with placebo in adult subjects with…
- Trial name
- NCT01721317
- Testing
- Ezogabine/Retigabine IR
- Where
- 11 sites in United States, Greece
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants, Epilepsy
A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil
The purpose of the study in Part 1, is to evaluate (under fasted conditions) the plasma pharmacokinetics (PK) of padsevonil (PSL) using 4 PSL product variants against a PSL reference tablet and in Part 2, to evaluate the PK of…
- Trial name
- NCT04283136
- Testing
- Padsevonil type 1 Tablet 200 mg, Padsevonil type 2 Tablet, Padsevonil type 3 Tablet
- Volunteers
- healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Epilepsy
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.
- Trial name
- NCT02172755
- Testing
- BIA 2-093
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Seizures
A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia.
- Trial name
- DEPAKINE PASS (NCT06714448)
- Testing
- Sodium valporate
- Where
- France
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hearing Loss
Evaluation of Software for Self-Fitting of Hearing Aids by People With Hearing Loss
The purpose of the study is to evaluate the efficacy of a prototype app for the self-fitting of hearing aids.
- Trial name
- NCT05280808
- Testing
- Experimental phone app used for self-fitting of hearing aids
- Where
- Australia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Sonova AG
Epilepsy, Alzheimer Disease
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT07222878
- Testing
- NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Epilepsy
An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls. The trial consisted of a screening visit, a treatment phase and a follow-up visit.
- Trial name
- NCT02281526
- Testing
- BIA 2-093
- Where
- South Africa
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women
- Trial name
- NCT02283788
- Testing
- BIA 2-093, Moxifloxacin
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Mild to Moderate Sensorineural Hearing Loss
Study of SelfFit Mobile Medical App for Hearing Loss Diagnostics and Hearing Device Fitting / Fine Tuning
The purpose of this clinical study is to validate the comparability of prescription formula fitting of hearing aids based on full diagnostic audiometry and SelfFit interactive fitting of hearing aids based on hearing loss…
- Trial name
- SelfFit (NCT01877317)
- Testing
- SelfFit adjusted hearing device
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Two Pi Signalprocessing Applications GmbH
Epilepsy
Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate
Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects.
- Trial name
- NCT02288312
- Testing
- BIA 2-093
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
Randomized, double-blind, placebo-controlled, sequential multiple ascending dose study to determine a maximum tolerated dose
- Trial name
- NCT01879332
- Testing
- BIA 2-093 3000 mg once daily, BIA 2-093 3600 mg once daily
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Partial Epilepsy
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to…
- Trial name
- NCT00900237
- Testing
- Eslicarbazepine acetate, Oxcarbazepine
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.